After having assessed the briefing package and where applicable the documentation referred to in Article 7(4), the JSC Subgroup, via the HTA secretariat, shall share with the health technology developer the list of issues indicating the topics to be addressed at the meeting referred to in Article 18(7) of Regulation (EU) 2021/2282 and where relevant the specific questions to be addressed only in writing before that meeting (‘the list of issues’). The health technology developer shall provide the JSC Subgroup, via the HTA secretariat, with written responses, if any, to the list of issues as well as any necessary materials or presentations for the meeting at the latest 10 days before that meeting.
In addition to the rules set out in paragraph 1, where the joint scientific consultation on medicinal products is carried out in parallel with the scientific advice, the following shall apply:
the JSC Subgroup, via the HTA secretariat, and the European Medicines Agency shall send their respective lists of issues to the health technology developer within the deadline set in the timetable referred to in Article 4(1);
the HTA secretariat and the European Medicines Agency shall exchange with each other the lists of issues on the same day as sending them to the health technology developer;
the health technology developer shall send to the JSC Subgroup, via the HTA secretariat, a copy of their written responses, if any, to the list of issues provided by the European Medicines Agency at the same time as it sends those responses to the European Medicines Agency;
the health technology developer shall send to the European Medicines Agency a copy of their written responses, if any, to the list of issues provided by the JSC Subgroup at the same time as it sends those responses to the JSC Subgroup, via the HTA secretariat.